Historical Valuation
TRANSTHERA-B (02617) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of TRANSTHERA-B (02617) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：95.25
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
TRANSTHERA-B (02617) has a current Price-to-Book (P/B) ratio of 69.27. Compared to its 3-year average P/B ratio of 78.95 , the current P/B ratio is approximately -12.26% higher. Relative to its 5-year average P/B ratio of 78.95, the current P/B ratio is about -12.26% higher. TRANSTHERA-B (02617) has a Forward Free Cash Flow (FCF) yield of approximately -0.64%. Compared to its 3-year average FCF yield of -0.74%, the current FCF yield is approximately -13.42% lower. Relative to its 5-year average FCF yield of -0.74% , the current FCF yield is about -13.42% lower.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of 02617 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 02617 in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is 02617 currently overvalued or undervalued?
TRANSTHERA-B (02617) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of TRANSTHERA-B (02617) is between to according to relative valuation methord.
What is TRANSTHERA-B (02617) fair value?
02617's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of TRANSTHERA-B (02617) is between to according to relative valuation methord.
How does 02617's valuation metrics compare to the industry average?
The average P/S ratio for 02617's competitors is , providing a benchmark for relative valuation. TRANSTHERA-B Corp (02617) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for TRANSTHERA-B (02617) as of Jan 15 2026?
As of Jan 15 2026, TRANSTHERA-B (02617) has a P/B ratio of 69.27. This indicates that the market values 02617 at 69.27 times its book value.
What is the current FCF Yield for TRANSTHERA-B (02617) as of Jan 15 2026?
As of Jan 15 2026, TRANSTHERA-B (02617) has a FCF Yield of -0.64%. This means that for every dollar of TRANSTHERA-B’s market capitalization, the company generates -0.64 cents in free cash flow.
What is the current Forward P/E ratio for TRANSTHERA-B (02617) as of Jan 15 2026?
As of Jan 15 2026, TRANSTHERA-B (02617) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of TRANSTHERA-B’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for TRANSTHERA-B (02617) as of Jan 15 2026?
As of Jan 15 2026, TRANSTHERA-B (02617) has a Forward P/S ratio of 0.00. This means the market is valuing 02617 at $0.00 for every dollar of expected revenue over the next 12 months.